FOR UK HEALTHCARE PROFESSIONALS ONLY

Clinical Data

For more information about Sevodyne, please see the prescribing information.

Sevodyne meets all the relevant regulatory requirements of a bioequivalent medicine (reference product: Norspan® [(buprenorphine patches) Mundipharma Gmbh, Germany]/BuTrans® [(buprenorphine patches) Napp Pharmaceuticals Ltd, UK]).1 Two bioequivalence studies were performed, one single-dose study and a multi-dose study, and an adhesion study was also performed.1

Single-dose study comparing Sevodyne 20 microgram/hr transdermal patch and Norspan 20 microgram/hr transdermal patch

Multiple-dose study comparing Sevodyne 20 microgram/hr transdermal patch
and Norspan 20 microgram/hr transdermal patch

sevodynemultiplev2

The adhesion study showed that both Sevodyne and Norspan had overall mean adherence (over 168 hours of patch wear) higher than 90%.1

References: 1) Data on file, 1010067149 v 5.0 September 2021
Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.www.mhra.gov.uk/yellowcard

SEV1010311E1_NOV2022

More products available
in this range:
Click to view their
individual websites